Novavax, Inc. (NASDAQ:NVAX) went down by -0.13% from its latest closing price when compared to the 1-year high value of $43.40 and move down -446.6%, while NVAX stocks collected +8.62% of gains with the last five trading sessions. The Wall Street Journal reported on 02/18/20 that Sanofi to Work on Virus Vaccine

Novavax, Inc. (NASDAQ:NVAX) Worth an Investment?

Novavax, Inc. (NASDAQ: NVAX) The 36 Months beta value for NVAX stocks is at 1.93, while of the analysts out of 0 who provided ratings for Novavax, Inc. stocks as a “buy” while as overweight, rated it as hold and as sell. The average price we get from analysts is $13.75 which is $5.81 above current price. NVAX currently has a short float of 18.31% and public float of 31.92 M with average trading volume of 4.13M shares.

NVAX Market Performance

NVAX stocks went up by 8.62% for the week, with the monthly drop of -19.14% and a quarterly performance of 107.31%, while its annual performance rate touched -80.15%. The simple moving average for the period of the last 20 days is 8.34% for NVAX stocks with the simple moving average of 48.00% for the last 200 days.

Analysts’ Opinion on Novavax, Inc. (NASDAQ:NVAX)

Many brokerage firms have already submitted their reports for NVAX stocks, with B. Riley FBR repeating the rating for NVAX shares by setting it to “Buy”. The predicted price for NVAX socks in the upcoming period according to B. Riley FBR is $12 based on the research report published on November 27, 2019.

H.C. Wainwright, on the other hand, stated in their research note that they expect to see NVAX stock at the price of $17, previously predicting the value of $10. The rating they have provided for NVAX stocks is “Buy” according to the report published on August 14, 2019.

Piper Jaffray gave “ Underweight” rating to NVAX stocks, setting the target price at $0.25 in the report published on February 28, 2019.

NVAX Stocks 42.68% Far from 50 Day Moving Average

After a stumble in the market that brought NVAX to its low price for the period of the last 52 weeks, Novavax, Inc. was unable to take a rebound, for now settling with -81.71% of loss for the given period.

The stock volatility was left at 10.37%, however, within the period of a single month, the volatility rate increased by 6.98%, while the shares surge at the distance of +11.99% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +82.53% upper at the present time.

In the course of the last 5 trading sessions, NVAX went up by +8.62%, which changed the moving average for the period of 200 days to the total of -13.96% of losses for the stock in comparison to the 20-day moving average settled at $7.37. In addition, Novavax, Inc. saw 99.50% in overturn over the period of a single year with a tendency to cut further gains.

NVAX Stock Insider Trading

Reports are indicating that there were more than several insider trading activities at Novavax, Inc. (NVAX), starting from Glenn Gregory M, who bought 1,250 shares at the price of $3.86 back on Jan 31. After this action, Rushing now owns 1,373 shares of Novavax, Inc., valued at $4,825 with the latest closing price.

MCMANUS MICHAEL A JR, the Director of Novavax, Inc., sold 3,929 shares at the value of $3.82 during a trade that took place back on Nov 18, which means that MCMANUS MICHAEL A JR is holding 9,951 shares at the value of $15,015 based on the most recent closing price.

NVAX Stock Fundamentals

The current profitability levels are settled at -507.23 for the present operating margin. The net margin for Novavax, Inc. stands at -538.81. Total capital return value is set at -94.71, while invested capital returns managed to touch -100.60. Equity return holds the value 86.60%, with -76.70% for asset returns.